Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 2
2001 1
2003 2
2005 1
2006 5
2007 5
2008 6
2009 10
2010 17
2011 13
2012 15
2013 13
2014 14
2015 12
2016 11
2017 15
2018 16
2019 23
2020 22
2021 17
2022 13
2023 9
2024 12
2025 9
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Results by year

Filters applied: . Clear all
Page 1
Pralatrexate for lymphoma.
[No authors listed] [No authors listed] Aust Prescr. 2019 Apr;42(2):77. doi: 10.18773/austprescr.2019.020. Epub 2019 Feb 28. Aust Prescr. 2019. PMID: 31048945 Free PMC article. Review. No abstract available.
Pralatrexate.
[No authors listed] [No authors listed] 2016 May 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 May 1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643237 Free Books & Documents. Review.
Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T cell lymphomas. Pralatrexate has been associated with a modest rate of serum enzyme elevations during therapy, but has not been convincingly …
Pralatrexate is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of peripheral T cell ly …
Pralatrexate for Peripheral T-Cell Lymphoma (PTCL): Chance Only Supports The Prepared Mind.
Altınay S, Kural A, Özmen A, Tural D, Tutar Y. Altınay S, et al. Anticancer Agents Med Chem. 2023;23(3):298-305. doi: 10.2174/1871520622666220610151603. Anticancer Agents Med Chem. 2023. PMID: 35692151 Review.
The enhanced polyglutamylation ability of pralatrexate is associated with increased tumor cell death and ultimately improved anticancer activity. Pralatrexate is considered a promising drug for patients with recurrent and treatment-resistant PTCL with a good surviva …
The enhanced polyglutamylation ability of pralatrexate is associated with increased tumor cell death and ultimately improved anticanc …
Methotrexate and Pralatrexate.
Wood GS, Wu J. Wood GS, et al. Dermatol Clin. 2015 Oct;33(4):747-55. doi: 10.1016/j.det.2015.05.009. Epub 2015 Aug 1. Dermatol Clin. 2015. PMID: 26433846 Free PMC article. Review.
This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorders. ...
This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphoma …
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. O'Connor OA, et al. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245435 Free PMC article. Clinical Trial.
This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity. PATIENTS AND METHODS: Patients with independently confirmed PTCL who progressed following 1 line of prior therapy received pralatrexate intravenously at 3 …
This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity. PATIENTS AND METHODS: …
Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Jennifer C Z, Sara Mohamed J, Salma A, Francine F. Jennifer C Z, et al. Expert Rev Hematol. 2020 Jun;13(6):577-583. doi: 10.1080/17474086.2020.1756257. Epub 2020 Apr 26. Expert Rev Hematol. 2020. PMID: 32293930 Review.
AREAS COVERED: This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T-cell lymphoma. Pharmacokinetics and mechanism of action of pralatrexate are discussed as well as its clinical efficacy and safety in …
AREAS COVERED: This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T …
Pralatrexate: treatment of T-cell non-Hodgkin's lymphoma.
Parker T, Barbarotta L, Foss F. Parker T, et al. Future Oncol. 2013 Jan;9(1):21-9. doi: 10.2217/fon.12.168. Future Oncol. 2013. PMID: 23252560 Review.
Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. Pralatrexate …
Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum …
Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
O'Connor OA. O'Connor OA. Curr Opin Oncol. 2006 Nov;18(6):591-7. doi: 10.1097/01.cco.0000245309.74767.20. Curr Opin Oncol. 2006. PMID: 16988580 Review.
Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL. RECENT FINDINGS: The high affinity of pralatrexate for RFC-1 significantly improves its internalization into cells. ...Early phase studies have shown marked ac …
Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against TCL. RECENT FINDINGS: The high …
Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
Shimanovsky A, Dasanu CA. Shimanovsky A, et al. Expert Opin Pharmacother. 2013 Mar;14(4):515-23. doi: 10.1517/14656566.2013.770474. Epub 2013 Feb 14. Expert Opin Pharmacother. 2013. PMID: 23409799 Review.
INTRODUCTION: Pralatrexate is a novel antifolate agent that belongs to the class of 10-deazaaminopterins. ...AREAS COVERED: This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. In addition, the authors highlig …
INTRODUCTION: Pralatrexate is a novel antifolate agent that belongs to the class of 10-deazaaminopterins. ...AREAS COVERED: This pape …
Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
O'Connor OA, Amengual J, Colbourn D, Deng C, Sawas A. O'Connor OA, et al. Leuk Lymphoma. 2017 Nov;58(11):2548-2557. doi: 10.1080/10428194.2017.1306642. Leuk Lymphoma. 2017. PMID: 28738754 Review.
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). ...In this review, we will bring the reader up to date on the many new aspec …
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatme …
233 results